OmniAb Inc. has announced the launch of OmniUltra™, its newest technology platform and expansion in the field of antibody discovery. The company will showcase OmniUltra, described as the industry's only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at a virtual investor event on December 15, 2025. Management will provide an overview of the platform's market applications and its strategic importance to OmniAb's business during the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251204562934) on December 04, 2025, and is solely responsible for the information contained therein.